1. The present study was designed to compare and contrast the effects of 1 year's treatment with angiotensin-converting enzyme inhibition ( @entity3371 25-100 mg daily) and beta-blockade ( @entity2165 50-100 mg daily) on @entity101 @entity299 and function as well as the other established cardiovascular risk factors of @entity101 (BP), lipid profile and blood @entity413 . 2. This was a prospective randomized open drug trial with blinded end-point echocardiographic and cardiac Doppler assessment in 37 subjects who had primary essential @entity101 and @entity4346 of @entity3371 (n = 20) versus @entity2165 (n = 17), adding @entity918 if BP was not controlled by 1 month. Multiple time point measurements throughout the 1 year treatment period of the study were made of BP, echocardiographic parameters of @entity299 and function, as well as lipid profile and blood @entity413 . 3. There were no significant between-group differences for @entity3371 or @entity2165 with regard to BP (at baseline (mean +/- SD) 154.0/101.1 +/- 13.3/5.1 and 152.5/101.8 +/- 10.0/5.8 mmHg, respectively) which was normalized by 1 month (138.7/85.6 +/- 18.8/11.7 and 135.4/88.5 +/- 16.9/9.5 mmHg, respectively) in both treatment groups (both P < 0.01 vs baseline). Also, there were no between-group or within-group differences for any of the measures of @entity4346 or systolic function throughout the 12 month treatment period; however, @entity3371 alone significantly increased left ventricular early diastolic filling (P < 0.05 vs baseline) at most of the measured time points. Furthermore, there were no significant between- or within-group differences with regard to metabolic (lipids and @entity413 ) profile over the 1 year treatment period of the present study. 4. Markers of cardiovascular risk, including BP, echocardiographic measures of @entity4346 , lipid profile and blood @entity413 were not significantly different between therapies. Despite good BP control by 1 month, neither drug regimen regressed @entity4346 . However, @entity3371 significantly increased left ventricular early diastolic filling after 3 months of treatment.

Absence of detectable regression of human @entity101 XXXX following drug treatment for 1 year.

@entity101 :: ('MESH:D006973', 'Disease') :: ['high blood pressure', 'hypertension', 'hypertensive'] @entity918 :: ('MESH:D006852', 'Chemical') :: ['hydrochlorothiazide'] @entity3371 :: ('CHEBI:3380', 'Chemical') :: ['captopril'] @entity4346 :: ('MESH:D017379', 'Disease') :: ['left ventricular hypertrophy'] @entity299 :: ('MESH:D006331', 'Disease') :: ['cardiac structure'] @entity2165 :: ('MESH:D001262', 'Chemical') :: ['atenolol'] @entity413 :: ('MESH:D005947', 'Chemical') :: ['glucose']
@entity4346 :: (MESH:D017379,Disease) :: ['left ventricular hypertrophy']
